International Myeloma Society (IMS)

The International Myeloma Society (IMS) is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide. The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners. IMS is governed by a Board of Directors representing practices from around the world and encourages and promotes the study of this expanding field through its annual International Myeloma Meeting.

Daratumumab-Based Quad Regimen (D-RVd) Improves Depth of Response in Transplant-Eligible NDMM: GRIFFIN Study

IMW 2019

Researchers report promising findings for a novel quad regimen, D-RVd, compared with RVd in patients with newly diagnosed multiple myeloma (NDMM) who are eligible for autologous stem-cell transplant. Read More ›

Real-World Outcomes of Triple-Class Refractory, Penta-Exposed RRMM

IMW 2019

A retrospective analysis suggests improved survival outcomes with selinexor plus dexamethasone compared with standard treatments in triple-class relapsed or refractory multiple myeloma (RRMM). Read More ›

SC Daratumumab Combined with Standard MM Regimens: Open-Label, Multicenter, Phase 2 Study: PLEIADES

IMW 2019

New data suggest that combinations using a subcutaneous (SC) co-formulation of daratumumab with recombinant human hyaluronidase have similar clinical activity and safety as intravenous daratumumab in patients with newly diagnosed multiple myeloma (MM). Read More ›

First-in-Human Study of AMG 420, an Anti-BCMA Bispecific T-Cell Engager (BiTE®), for Relapsed or Refractory Multiple Myeloma

IMW 2019

This first-in-human study shows that AMG 420, a BiTE antibody that directs the immune system to target B-cell maturation antigen (BCMA) on the tumor cell and CD3 on T-cells, may be effective and safe. Read More ›

Melflufen in RRMM with Extramedullary Disease: Phase 2 HORIZON Study

IMW 2019

Researchers report positive data for patients with relapsed or refractory multiple myeloma (RRMM) and extramedullary disease in the phase 2 HORIZON study of melflufen plus dexamethasone. Read More ›

CT053, Anti-BCMA CAR T-Cell Therapy, for Relapsed or Refractory MM: Proof of Concept

IMW 2019

This phase 1 study demonstrates that CT053, a B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell product, is effective and safe in patients with multiply relapsed multiple myeloma (MM). Read More ›

Safety of Rapid Daratumumab Infusion in RRMM

IMW 2019

This study reports successful administration of intravenous daratumumab over 90 minutes for patients with relapsed or refractory multiple myeloma (RRMM). Read More ›